Well, what I think this combination does, it has a roadway, a pathway to having approval based on randomized clinical trials that are still accruing and we have to read out. And that would bring another player into the sphere of melanoma therapeutics. And that’s important to look at the ability to utilize this as a backbone for further clinical trials, whether they’re triplet, whether they’re in brain metastases, whether they’re in adjuvant or neoadjuvant...
Well, what I think this combination does, it has a roadway, a pathway to having approval based on randomized clinical trials that are still accruing and we have to read out. And that would bring another player into the sphere of melanoma therapeutics. And that’s important to look at the ability to utilize this as a backbone for further clinical trials, whether they’re triplet, whether they’re in brain metastases, whether they’re in adjuvant or neoadjuvant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.